- Home
- DBRG vs DAWN Comparison
DBRG vs DAWN Comparison
Compare DBRG & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DBRG | DAWN |
|---|---|---|
| Founded | 1991 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.2B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | DBRG | DAWN |
|---|---|---|
| Price | $15.58 | $21.47 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 8 |
| Target Price | $16.00 | ★ $24.43 |
| AVG Volume (30 Days) | ★ 2.7M | 2.1M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.26% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $158,182,000.00 |
| Revenue This Year | $373.39 | $55.03 |
| Revenue Next Year | $8.23 | $28.12 |
| P/E Ratio | $252.25 | ★ N/A |
| Revenue Growth | N/A | ★ 20.60 |
| 52 Week Low | $7.64 | $5.64 |
| 52 Week High | $15.60 | $21.50 |
Technical Indicators
Market Signals| Indicator | DBRG | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 69.79 | 80.51 |
| Support Level | $15.33 | $10.30 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.05 | 0.04 |
| MACD | 0.02 | -0.36 |
| Stochastic Oscillator | 89.36 | 81.25 |
Price Performance
Historical ComparisonAbout DBRG DigitalBridge Group Inc.
DigitalBridge Group Inc is a developer of alternative asset manager dedicated to investing in digital infrastructure. The company's platform invests in and operates businesses across the digital ecosystem, including cell towers, data centres, fiber, small cells, and edge infrastructure, to provide clients with funds for digital infrastructure real estate infrastructure.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.